Propanc Biopharma Inc (PPCB) will initiate the world-first Phase 1b first-in-human study of PRP in February 2027. First-in-human trial initiation marks major pipeline advancement for the company.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 0.01 | 0.02 | 0.01 | 0.44 |
| Receivables | 0.00 | 0.00 | 0.01 | 0.01 |
| Inventory | — | — | — | — |
| Other | — | 0.00 | 0.00 | 0.04 |
| 0.02 | 0.03 | 8.35 | 8.22 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.97 | 1.21 | 1.25 | 0.97 |
| ST’ Debt | 0.11 | 0.27 | 0.48 | 0.47 |
| Other | 1.04 | 0.80 | 1.07 | 0.89 |
| 3.16 | 3.79 | 5.58 | 3.48 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Year |
|---|
| Sep | Dec | Mar | Jun | Year | |
|---|---|---|---|---|---|
| ’26 | (1.94) | (1.00) | (1.14) | — |
—
|
| ’25 | (0.24) | 0.02 | (0.10) | (0.09) |
(0.41)
|
| ’24 | (0.33) | (0.24) | (0.10) | (0.26) |
(0.94)
|
| ’23 | (0.51) | (0.23) | (0.19) | (0.18) |
(1.11)
|
| ’22 | (0.49) | (0.22) | (0.31) | (0.41) |
(1.44)
|
| ’21 | (0.18) | (0.26) | (0.47) | (0.24) |
(1.15)
|
| ’20 | (0.73) | (0.42) | (0.21) | (0.50) |
(1.85)
|
| Sep | Dec | Mar | Jun | Year | |
|---|---|---|---|---|---|
| ’26 | (1.94) | (1.00) | (1.14) | — |
—
|
| ’25 | (0.24) | 0.02 | (0.10) | (0.09) |
(0.41)
|
| ’24 | (0.33) | (0.24) | (0.10) | (0.26) |
(0.94)
|
| ’23 | (0.51) | (0.23) | (0.19) | (0.18) |
(1.11)
|
| ’22 | (0.49) | (0.22) | (0.31) | (0.41) |
(1.44)
|
| ’21 | (0.18) | (0.26) | (0.47) | (0.24) |
(1.15)
|
| ’20 | (0.73) | (0.42) | (0.21) | (0.50) |
(1.85)
|
| Sep | Dec | Mar | Jun | Year | |
|---|---|---|---|---|---|
| ’26 | (9.75) | (7.50) | (7.00) | — |
—
|
| ’25 | 0.00 | (805.75) | (312.50) | — |
(371.25)
|
| ’24 | (62.50k) | (46.87k) | (15.62k) | — |
(31.25k)
|
| ’23 | 0.00 | 0.00 | 0.00 | — |
(2.81m)
|
| ’22 | (31.25m) | (31.25m) | (15.62m) | 0.00 |
(78.12m)
|
| ’21 | 0.00 | (703.12m) | (187.50m) | — |
(1000.00m)
|
| ’20 | (1000.00m) | (1000.00m) | (1000.00m) | — |
(1000.00m)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.00 | 0.36 | 0.01 | 0.01 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,250.00 | 55.00 | 0.79 | 3,636.50 | — | — | — |
High Price
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 3 | 2 | 2 | 2 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.71) | (2.79) | (1.95) | (58.92) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.66) | (2.66) | (1.82) | (58.92) | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | — | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (78,125,000.00) | (2,812,500.00) | (31,250.00) | (371.25) | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (21.06) | (0.64) | (9,351.00) | (2.55) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (21.06) | (0.64) | (9,351.00) | (2.55) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (44.33) | (1.79) | (37,791.00) | 87.63 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.07 | 1.74 | 0.00 | 0.16 | — | — | — |
Shares
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.44) | (1.11) | (0.94) | (0.41) | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | — | — | ‡‡‡‡‡ | — | — | — | — | — | — | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.44) | (1.11) | (0.94) | (0.41) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.05) | (3.14) | (3.77) | 2.77 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.05 | 0.11 | 0.32 | 0.59 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.05 | 0.10 | 0.30 | 0.57 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.02) | (3.12) | (3.78) | 13.91 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7,085.23%) | (4,403.94%) | (3,034.66%) | (598.08%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | (247.22%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 110.09% | 101.75% | 58.39% | (1,163.68%) | — | — | — |
ROE
|
Propanc Biopharma Inc. (PPCB), a pre-revenue microcap biotech developing the oncology candidate Prolindac, embodies the speculative perils of clinical-stage drug development, with no sales in over a decade and reliance on dilutive equity raises and grants. Losses have narrowed impressively from -$9.4 million in 2016 to -$1.8 million in 2024, alongside an 80% reduction in cash burn, but projections signal a dire reversal with a forecasted -$58.9 million net loss in 2025 amid escalating R&D costs. This lean operation—run by just 2-3 employees—shows operational discipline yet underscores profound scalability risks and vulnerability to trial delays in a sector where 90%+ of candidates fail.
The balance sheet reveals chronic fragility: persistently negative shareholders’ equity through 2024 (-$3.8 million), rising debt (up 928% to $586,200 projected), and episodic cash bleeds that have eroded stock prices by over 99.999% from historic peaks. Recent financings offer short-term working capital relief (+$2.8 million projected), but razor-thin cash runways demand constant capital infusions, fueling dilution and price volatility tied to milestones like Prolindac’s Phase IIb trial data expected in 2025-2026. Absent insider buying and OTCQB listing pressures amplify execution doubts.
For risk-averse investors, PPCB is a high-downside lottery ticket—watchlist material at best, with no allocation beyond 1% absent positive trial breakthroughs that could attract partnerships. While projections hint at explosive upside (prices potentially 69,000% higher), history favors capital preservation over such binary bets; the full analysis dissects these correlations in detail.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.